-1752956459196.webp&w=3840&q=75)
2025 NOSCM | Upper GI Cancer: Esophageal and Gastric-New Developments
0% Complete
Course Overview
Dr. Thomas Reske highlighted upper GI cancer advances, noting a 46% OS benefit with adjuvant nivolumab (Checkmate 577) and strong survival with FLOT+nivolumab (Matterhorn). Trastuzumab deruxtecan cut progression risk by 30% (Destiny 04). Claudin, CAR T, and antibody-drug conjugates show promise.
Course Content
This material is non-CME, no credits are available, and a certificate will not be provided upon completion.
Course Details
- Duration
- 0.00 hour
- Released
- Jul 20, 2025
- Last Review
- Jul 20, 2025
- Expires
- Jul 20, 2026
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
Faculty & Disclosure
Faculty
Thomas Reske, MD, PhD, FACP, CMD, AGSF
Accreditation
NA
-1773064516362.webp&w=3840&q=75)
-1773063846465.webp&w=3840&q=75)